Phase 1 · NCT03841630
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects
CompletedVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
- ClinicalTrials.gov ID
- NCT03841630
- Indication
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 45
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 21 Years – 65 Years
- Locations
- 1 site · Singapore
- Study start
- 13 Mar 2019
- Primary completion
- 25 Jul 2019
- Study completion
- 25 Jul 2019
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 6 Aug 2019
Endpoints
Primary
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary
Pharmacokinetics: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3437943; Pharmacokinetics: Maximum Concentration (Cmax) of LY3437943; Pharmacokinetics: Time to Maximum Concentration (Tmax) of LY3437943